Table of Contents
Journal of Computational Medicine
Volume 2013 (2013), Article ID 406049, 38 pages
http://dx.doi.org/10.1155/2013/406049
Review Article

SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated Receptor γ Activators: A Perspective

Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), S. A. S. Nagar, Punjab 160062, India

Received 28 November 2012; Accepted 28 January 2013

Academic Editor: Michele Migliore

Copyright © 2013 Vaibhav A. Dixit and Prasad V. Bharatam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, “Global prevalence of diabetes: estimates for the year 2000 and projections for 2030,” Diabetes Care, vol. 27, no. 5, pp. 1047–1053, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Pourcet, J. C. Fruchart, B. Staels, and C. Glineur, “Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis,” Expert Opinion on Emerging Drugs, vol. 11, no. 3, pp. 379–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. H. van Huijsduijnen, W. H. B. Sauer, A. Bombrun, and D. Swinnen, “Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs,” Journal of Medicinal Chemistry, vol. 47, no. 17, pp. 4142–4146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. D. E. Moller, “New drug targets for type 2 diabetes and the metabolic syndrome,” Nature, vol. 414, no. 6865, pp. 821–827, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. DeSouza and V. Fonseca, “Therapeutic targets to reduce cardiovascular disease in type 2 diabetes,” Nature Reviews Drug Discovery, vol. 8, pp. 361–367, 2009. View at Publisher · View at Google Scholar
  6. N. Cho and Y. Momose, “Peroxisome proliferator-activated receptor γ agonists as insulin sensitizers: from the discovery to recent progress,” Current Topics in Medicinal Chemistry, vol. 8, pp. 1483–1507, 2008. View at Publisher · View at Google Scholar
  7. B. Panunti, A. A. Jawa, and V. A. Fonseca, “Mechanisms and therapeutic targets in type 2 diabetes mellitus,” Drug Discovery Today: Disease Mechanisms, vol. 1, no. 2, pp. 151–157, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. K. Arulmozhi and B. Portha, “GLP-1 based therapy for type 2 diabetes,” European Journal of Pharmaceutical Sciences, vol. 28, no. 1-2, pp. 96–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Rosen, “The rosiglitazone story—lessons from an FDA advisory committee meeting,” The New England Journal of Medicine, vol. 357, pp. 844–846, 2007. View at Publisher · View at Google Scholar
  11. M. T. Smith, “Mechanisms of troglitazone hepatotoxicity,” Chemical Research in Toxicology, vol. 16, no. 6, pp. 679–687, 2003. View at Publisher · View at Google Scholar
  12. M. Chandran, S. A. Phillips, T. Ciaraldi, and R. R. Henry, “Adiponectin: more than just another fat cell hormone?” Diabetes Care, vol. 26, no. 8, pp. 2442–2450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. A. H. Knoll, “The early evolution of eukaryotes: a geological perspective,” Science, vol. 256, no. 5057, pp. 622–627, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. M. E. Greene, B. Blumberg, O. W. McBride et al., “isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995. View at Google Scholar · View at Scopus
  15. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Hendlich, F. Rippmann, and G. Barnickel, “LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins,” Journal of Molecular Graphics and Modelling, vol. 15, no. 6, pp. 359–363, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. “The PyMOL Molecular Graphics System, Version 1.5.0.1,” Schrödinger, LLC.
  19. V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the intact PPAR-γ-RXR-α nuclear receptor complex on DNA,” Nature, vol. 456, no. 7220, pp. 350–356, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Sohda, K. Mizuno, E. Imamiya, H. Tawada, K. Meguro, and Y. Kawamatsu Yamamoto, “Studies on antidiabetic agents. III. 5-arylthiazolidine-2, 4-diones as potent aldose reductase inhibitors,” Chemical and Pharmaceutical Bulletin, vol. 30, pp. 3601–3616, 1982. View at Publisher · View at Google Scholar
  21. C. Pirat, A. Farce, N. Lebegue et al., “Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators,” Medicinal Chemistry, vol. 55, no. 9, pp. 4027–4061, 2012. View at Publisher · View at Google Scholar
  22. R. T. Gampe Jr., V. G. Montana, M. H. Lambert et al., “Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors,” Molecular Cell, vol. 5, no. 3, pp. 545–555, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Molecular recognition of fatty acids by peroxisome proliferator-activated receptors,” Molecular Cell, vol. 3, no. 3, pp. 397–403, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Cronet, J. F. W. Petersen, R. Folmer et al., “Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family,” Structure, vol. 9, no. 8, pp. 699–706, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. H. E. Xu, M. H. Lambert, V. G. Montana et al., “Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13919–13924, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. H. E. Xu, T. B. Stanley, V. G. Montana et al., “Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα,” Nature, vol. 415, no. 6873, pp. 813–817, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Sauerberg, I. Pettersson, L. Jeppesen et al., “Novel tricyclic-α-alkyloxyphenylpropionic acids: dual PPARα/γ agonists with hypolipidemic and antidiabetic activity,” Journal of Medicinal Chemistry, vol. 45, no. 4, pp. 789–804, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Ebdrup, I. Pettersson, H. B. Rasmussen et al., “Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar,” Journal of Medicinal Chemistry, vol. 46, no. 8, pp. 1306–1317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Östberg, S. Svensson, G. Selén et al., “A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects,” Journal of Biological Chemistry, vol. 279, no. 39, pp. 41124–41130, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Takada, R. T. Yu, H. E. Xu et al., “Alteration of a single amino acid in peroxisome proliferator-activated receptor-α (PPARα) generates a PPARδ phenotype,” Molecular Endocrinology, vol. 14, no. 5, pp. 733–740, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Q. Shi, J. F. Dropinski, B. M. McKeever et al., “Design and synthesis of α-aryloxyphenylacetic acid derivatives: a novel class of PPARα/γ dual agonists with potent antihyperglycemic and lipid modulating activity,” Journal of Medicinal Chemistry, vol. 48, no. 13, pp. 4457–4468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Li, M. Choi, K. Suino et al., “Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 27, pp. 9505–9510, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Mahindroo, C. F. Huang, Y. H. Peng et al., “Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities,” Journal of Medicinal Chemistry, vol. 48, no. 26, pp. 8194–8208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Fyffe, M. S. Alphey, L. Buetow et al., “Recombinant human PPAR-β/δ ligand-binding domain is locked in an activated conformation by endogenous fatty acids,” Journal of Molecular Biology, vol. 356, no. 4, pp. 1005–1013, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. A. Fyffe, M. S. Alphey, L. Buetow et al., “Reevaluation of the PPAR-β/δ ligand binding domain model reveals why it exhibits the activated form,” Molecular Cell, vol. 21, no. 1, pp. 1–2, 2006. View at Publisher · View at Google Scholar
  36. N. Mahindroo, C. C. Wang, C. C. Liao et al., “Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies,” Journal of Medicinal Chemistry, vol. 49, no. 3, pp. 1212–1216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Burgermeister, A. Schnoebelen, A. Flament et al., “A novel partial agonist of peroxisome proliferator-activated receptor-γ (PPARγ) recruits PPARγ-coactivator-1α, prevents triglyceride accumulation, and potentiates insulin signaling in vitro,” Molecular Endocrinology, vol. 20, no. 4, pp. 809–830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. I. L. Lu, C. F. Huang, Y. H. Peng et al., “Structure-based drug design of a novel family of PPARγ partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities,” Journal of Medicinal Chemistry, vol. 49, no. 9, pp. 2703–2712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Kuhn, H. Hilpert, J. Benz et al., “Structure-based design of indole propionic acids as novel PPARα/γ co-agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 15, pp. 4016–4020, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. R. Hopkins, S. V. O'Neil, M. C. Laufersweiler et al., “Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-γ binding agents with potential application to the treatment of osteoporosis,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 21, pp. 5659–5663, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Mahindroo, Y. H. Peng, C. H. Lin et al., “Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists,” Journal of Medicinal Chemistry, vol. 49, no. 21, pp. 6421–6424, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Pochetti, C. Godio, N. Mitro et al., “Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor γ ligand-binding domain in the complex with two enantiomeric ligands,” Journal of Biological Chemistry, vol. 282, no. 23, pp. 17314–17324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Epple, M. Azimioara, R. Russo et al., “3,4,5-trisubstituted isoxazoles as novel PPARδ agonists. Part 2,” Bioorganic & Medicinal Chemistry Letters, vol. 16, no. 21, pp. 5488–5492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. H. Oon Han, S. H. Kim, K. H. Kim et al., “Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 17, pp. 937–941, 2007. View at Publisher · View at Google Scholar
  45. A. L. B. Ambrosio, S. M. G. Dias, I. Polikarpov, R. B. Zurier, S. H. Burstein, and R. C. Garratt, “Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor γ,” Journal of Biological Chemistry, vol. 282, no. 25, pp. 18625–18633, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Einstein, T. E. Akiyama, G. A. Castriota et al., “The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities,” Molecular Pharmacology, vol. 73, no. 1, pp. 62–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. M. L. Sierra, V. Beneton, A. B. Boullay et al., “Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents,” Journal of Medicinal Chemistry, vol. 50, no. 4, pp. 685–695, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. P. Trump, J. E. Cobb, B. G. Shearer et al., “Co-crystal structure guided array synthesis of PPARγ inverse agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 14, pp. 3916–3920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. J. B. Bruning, M. J. Chalmers, S. Prasad et al., “Partial agonists activate PPARγ using a helix 12 independent mechanism,” Structure, vol. 15, no. 10, pp. 1258–1271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. I. Pettersson, S. Ebdrup, M. Havranek et al., “Design of a partial PPARδ agonist,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 16, pp. 4625–4629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Casimiro-Garcia, C. F. Bigge, J. A. Davis et al., “Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: synthesis, evaluation as PPARα/γ dual agonists, and X-ray crystallographic studies,” Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 4883–4907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Itoh, L. Fairall, K. Amin et al., “Structural basis for the activation of PPARγ by oxidized fatty acids,” Nature Structural & Molecular Biology, vol. 15, no. 9, pp. 924–931, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Keil, H. Matter, K. Schonafinger et al., “Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and invivo efficacy,” ChemMedChem, vol. 6, pp. 633–653, 2011. View at Publisher · View at Google Scholar
  54. C. Weidner, J. C. de Groot, A. Prasad et al., “Amorfrutins are potent antidiabetic dietary natural products,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, pp. 7257–7262, 2012. View at Publisher · View at Google Scholar
  55. T. Waku, T. Shiraki, T. Oyama et al., “Structural insight into PPARγ activation through covalent modification with endogenous fatty acids,” Journal of Molecular Biology, vol. 385, no. 1, pp. 188–199, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Waku, T. Shiraki, T. Oyama, K. Maebara, R. Nakamori, and K. Morikawa, “The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites,” The EMBO Journal, vol. 29, pp. 3395–3407, 2010. View at Publisher · View at Google Scholar
  57. T. Oyama, K. Toyota, T. Waku et al., “Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures,” Acta Crystallographica Section D, vol. 65, no. 8, pp. 786–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Waku, T. Shiraki, T. Oyama, and K. Morikawa, “Atomic structure of mutant PPARγ LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARγ/RXRα function by covalently bound ligands,” FEBS Letters, vol. 583, no. 2, pp. 320–324, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Ohashi, T. Oyama, I. Nakagome et al., “Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship,” Journal of Medicinal Chemistry, vol. 54, no. 1, pp. 331–341, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Wakabayashi, S. Hayashi, Y. Matsui et al., “Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, cerco-A,” Biological & Pharmaceutical Bulletin, vol. 34, no. 7, pp. 1094–1104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Montanari, F. Saccoccia, E. Scotti et al., “Crystal structure of the peroxisome proliferator-activated receptor γ (PPARγ) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design,” Journal of Medicinal Chemistry, vol. 51, no. 24, pp. 7768–7776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Zhang, D. E. Ryono, P. Devasthale et al., “Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR α/γ agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 1451–1456, 2009. View at Publisher · View at Google Scholar
  63. Y. Li, A. Kovach, K. Suino-Powell, D. Martynowski, and H. E. Xu, “Structural and biochemical basis for the binding selectivity of peroxisome proliferator-activated receptor γ to PGC-1α,” Journal of Biological Chemistry, vol. 283, no. 27, pp. 19132–19139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Li, J. Zhang, F. J. Schopfer et al., “Molecular recognition of nitrated fatty acids by PPARγ,” Nature Structural & Molecular Biology, vol. 15, no. 8, pp. 865–867, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. B. G. Shearer, H. S. Patel, A. N. Billin et al., “Discovery of a novel class of PPARδ partial agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 18, pp. 5018–5022, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. D. R. Artis, J. J. Lin, C. Zhang et al., “Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 1, pp. 262–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. U. Grether, A. Bénardeau, J. Benz et al., “Design and biological evaluation of novel, balanced dual PPARα/γ agonists,” ChemMedChem, vol. 4, no. 6, pp. 951–956, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Motani, Z. Wang, J. Weiszmann et al., “INT131: a selective modulator of PPARγ,” Journal of Molecular Biology, vol. 386, no. 5, pp. 1301–1311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Bénardeau, J. Benz, A. Binggeli et al., “Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 9, pp. 2468–2473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. C. H. Lin, Y. H. Peng, M. S. Coumar et al., “Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor γ agonists,” Journal of Medicinal Chemistry, vol. 52, no. 8, pp. 2618–2622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. R. V. Connors, Z. Wang, M. Harrison et al., “Identification of a PPARδ agonist with partial agonistic activity on PPARγ,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 13, pp. 3550–3554, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Fracchiolla, A. Laghezza, L. Piemontese et al., “New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors α/γ dual agonists with improved potency and reduced adverse effects on skeletal muscle function,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6382–6393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Casimiro-Garcia, C. F. Bigge, J. A. Davis et al., “Synthesis and evaluation of novel α-heteroaryl-phenylpropanoic acid derivatives as PPARα/γ dual agonists,” Bioorganic and Medicinal Chemistry, vol. 17, no. 20, pp. 7113–7125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Li, Z. Wang, N. Furukawa et al., “T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor γ binding properties,” Journal of Biological Chemistry, vol. 283, no. 14, pp. 9168–9176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Li, L. J. Kennedy, Y. Shi et al., “Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor α selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453),” Journal of Medicinal Chemistry, vol. 53, no. 7, pp. 2854–2864, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Furukawa, T. Arita, S. Satoh et al., “Discovery of a novel selective PPARγ modulator from (-)-cercosporamide derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 20, pp. 2095–2098, 2010. View at Publisher · View at Google Scholar
  77. A. Riu, M. Grimaldi, A. le Maire et al., “Peroxisome proliferator-activated receptor γ is a target for halogenated analogs of bisphenol A,” Environmental Health Perspectives, vol. 119, no. 9, pp. 1227–1232, 2011. View at Publisher · View at Google Scholar
  78. C. A. Luckhurst, L. A. Stein, M. Furber et al., “Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 1, pp. 492–496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Riu, A. le Maire, M. Grimaldi et al., “Characterization of novel ligands of ERα, Erβ, and PPARγ: the case of halogenated bisphenol A and their conjugated metabolites,” Toxicological Sciences, vol. 122, pp. 372–382, 2011. View at Publisher · View at Google Scholar
  80. K. A. Evans, B. G. Shearer, D. D. Wisnoski et al., “Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy,” Bioorganic & Medicinal Chemistry Letters, vol. 21, pp. 2345–2350, 2011. View at Publisher · View at Google Scholar
  81. J. Uppenberg, C. Svensson, M. Jaki, G. Bertilsson, L. Jendeberg, and A. Berkenstam, “Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ,” Journal of Biological Chemistry, vol. 273, no. 47, pp. 31108–31112, 1998. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Zhang, X. Xu, L. Chen et al., “Molecular determinants of magnolol targeting both RXRα and PPARγ,” PloS ONE, vol. 6, Article ID e28253, 2011. View at Publisher · View at Google Scholar
  83. A. Casimiro-Garcia, G. F. Filzen, D. Flynn et al., “Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ,” Journal of Medicinal Chemistry, vol. 54, no. 12, pp. 4219–4233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Porcelli, F. Gilardi, A. Laghezza et al., “Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity,” Journal of Medicinal Chemistry, vol. 55, pp. 37–54, 2012. View at Publisher · View at Google Scholar
  85. M. Sime, A. C. Allan, P. Chapman et al., “Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARγ partial agonist,” Bioorganic & Medicinal Chemistry Letters, vol. 21, pp. 5568–5572, 2011. View at Publisher · View at Google Scholar
  86. A. C. Puhl, A. Bernardes, R. L. Silveira et al., “Mode of peroxisome proliferator-activated receptor γ activation by luteolin,” Molecular Pharmacology, vol. 81, no. 6, pp. 788–799, 2012. View at Publisher · View at Google Scholar
  87. W. Liu, F. Lau, K. Liu et al., “Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators,” Journal of Medicinal Chemistry, vol. 54, pp. 8541–8554, 2011. View at Publisher · View at Google Scholar
  88. A. A. Amato, S. Rajagopalan, J. Z. Lin et al., “GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain,” The Journal of Biological Chemistry, vol. 287, pp. 28169–28179, 2012. View at Publisher · View at Google Scholar
  89. R. R. Malapaka, S. Khoo, J. Zhang et al., “Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors,” The Journal of Biological Chemistry, vol. 287, pp. 183–195, 2012. View at Publisher · View at Google Scholar
  90. A. Furukawa, T. Arita, T. Fukuzaki et al., “Substituents at the naphthalene C3 position of (-)-cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 22, pp. 1348–1351, 2012. View at Publisher · View at Google Scholar
  91. N. Kuwabara, T. Oyama, D. Tomioka et al., “Peroxisome proliferator-activated receptors (PPARS) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype,” Journal of Medicinal Chemistry, vol. 55, pp. 893–902, 2012. View at Publisher · View at Google Scholar
  92. Y. Amano, T. Yamaguchi, K. Ohno et al., “Structural basis for telmisartan-mediated partial activation of PPAR gamma,” Hypertension Research, vol. 35, pp. 715–719, 2012. View at Google Scholar
  93. J. L. Oberfield, J. L. Collins, C. P. Holmes et al., “A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6102–6106, 1999. View at Publisher · View at Google Scholar · View at Scopus
  94. T. S. Hughes, M. J. Chalmers, S. Novick et al., “Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism,” Structure, vol. 20, pp. 139–150, 2012. View at Publisher · View at Google Scholar
  95. R. S. Chana, A. J. Lewington, and N. J. Brunskill, “Differential effects of peroxisome proliferator activated receptor-γ (PPARγ) ligands in proximal tubular cells: thiazolidinediones are partial PPARγ agonists,” Kidney International, vol. 65, no. 6, pp. 2081–2090, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Yamagishi, K. Yamamoto, Y. Mochizuki, T. Nakano, S. Yamada, and H. Tokiwa, “Flexible ligand recognition of peroxisome proliferator-activated receptor-γ (PPARγ),” Bioorganic & Medicinal Chemistry Letters, vol. 20, no. 11, pp. 3344–3347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. C. G. Ji and J. Z. H. Zhang, “Protein polarization is critical to stabilizing AF-2 and helix-2 domains in ligand binding to PPAR-γ,” Journal of the American Chemical Society, vol. 130, no. 50, pp. 17129–17133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Henriksen, I. Byrjalsen, P. Qvist et al., “Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 4, pp. 392–401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Misra, R. Chakrabarti, R. K. Vikramadithyan et al., “PAT5A: a partial agonist of peroxisome proliferator-activated receptor γ is a potent antidiabetic thiazolidinedione yet weakly adipogenic,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 763–771, 2003. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Khanna, M. E. Sobhia, and P. V. Bharatam, “Additivity of molecular fields: CoMFA study on dual activators of PPARα and PPARγ,” Journal of Medicinal Chemistry, vol. 48, no. 8, pp. 3015–3025, 2005. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Fiévet, J.-C. Fruchart, and B. Staels, “PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, pp. 606–614, 2006. View at Publisher · View at Google Scholar
  102. I. Ahmed, K. Furlong, J. Flood, V. P. Treat, and B. J. Goldstein, “Dual PPAR α/γ agonists: promises and pitfalls in type 2 diabetes,” American Journal of Therapeutics, vol. 14, no. 1, pp. 49–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Xu, C. J. Rito, G. J. Etgen et al., “Design and synthesis of α-aryloxy-α-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor α/γ agonists,” Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2422–2425, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. B. C. Hansen, X. T. Tigno, A. Benardeau, M. Meyer, E. Sebokova, and J. Mizrahi, “Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome,” Cardiovascular Diabetology, vol. 10, p. 7, 2011. View at Publisher · View at Google Scholar
  105. S. L. Cox, “Tesaglitazar: a promising approach in type 2 diabetes,” Drugs of Today, vol. 42, no. 3, pp. 139–146, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. D. Conlon, “Goodbye glitazars?” British Journal of Diabetes & Vascular Disease, vol. 6, no. 3, pp. 135–137, 2006. View at Publisher · View at Google Scholar
  107. L. S. Higgins and A. M. DePaoli, “Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation,” The American Journal of Clinical Nutrition, vol. 91, pp. 267S–272S, 2009. View at Google Scholar
  108. S. Rocchi, F. Picard, J. Vamecq et al., “A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity,” Molecular Cell, vol. 8, no. 4, pp. 737–747, 2001. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Allen, F. Zhang, S. A. Moodie et al., “Halofenate is a selective peroxisome proliferator-activated receptor{gamma} modulator with antidiabetic activity,” Diabetes, vol. 55, no. 9, pp. 2523–2533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. T. Fujimura, C. Kimura, T. Oe et al., “A selective peroxisome proliferator-activated receptor γ modulator with distinct fat cell regulation properties,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 2, pp. 863–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Tagami, H. Yamamoto, K. Moriyama et al., “A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones,” Endocrinology, vol. 150, no. 2, pp. 862–870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. H. A. Pershadsingh and T. W. Kurtz, “Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease,” Diabetes Care, vol. 27, no. 4, p. 1015, 2004. View at Google Scholar · View at Scopus
  113. J. Rieusset, F. Touri, L. Michalik et al., “A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity,” Molecular Endocrinology, vol. 16, no. 11, pp. 2628–2644, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. H. M. Wright, C. B. Clish, T. Mikami et al., “A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation,” Journal of Biological Chemistry, vol. 275, no. 3, pp. 1873–1877, 2000. View at Publisher · View at Google Scholar · View at Scopus
  115. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure—activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at Scopus
  116. K. A. Reddy, B. B. Lohray, V. Bhushan et al., “Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives,” Journal of Medicinal Chemistry, vol. 42, no. 17, pp. 3265–3278, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. K. Matsumoto, S. Miyake, M. Yano, Y. Ueki, and Y. Tominaga, “Increase of lipoprotein (a) with troglitazone,” The Lancet, vol. 350, no. 9093, pp. 1748–1749, 1997. View at Google Scholar · View at Scopus
  118. K. Kawai, Y. Kawasaki-Tokui, T. Odaka et al., “Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs,” Arzneimittel-Forschung, vol. 47, no. 4, pp. 356–368, 1997. View at Google Scholar · View at Scopus
  119. B. B. Lohray, V. B. Lohray, A. C. Bajji et al., “(-)3-[4-[2-(phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity,” Journal of Medicinal Chemistry, vol. 44, no. 16, pp. 2675–2678, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. D. A. Brooks, G. J. Etgen, C. J. Rito et al., “Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids: a new class of dual PPARα/γ agonists,” Journal of Medicinal Chemistry, vol. 44, no. 13, pp. 2061–2064, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Sohda, K. Mizuno, and Y. Kawamatsu, “Studies on antidiabetic agents. VI. Asymmetric transformation of (±)-5-[4-(1-methylcyclohexylmethoxy)benzyl]-2,4-thiazolidinedione (ciglitazone) with optically active 1-phenylethylamines,” Chemical and Pharmaceutical Bulletin, vol. 32, no. 11, pp. 4460–4465, 1984. View at Publisher · View at Google Scholar · View at Scopus
  122. P. V. Bharatam and S. Khanna, “Rapid racemization in thiazolidinediones: a quantum chemical study,” Journal of Physical Chemistry A, vol. 108, no. 17, pp. 3784–3788, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. D. Haigh, G. Allen, H. C. Birrell et al., “Non-thiazolidinedione antihyperglycaemic agents. Part 3: the effects of stereochemistry on the potency of α-methoxy-β-phenylpropanoic acids,” Bioorganic and Medicinal Chemistry, vol. 7, no. 5, pp. 821–830, 1999. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Oguchi, K. Wada, H. Honma et al., “Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones,” Journal of Medicinal Chemistry, vol. 43, no. 16, pp. 3052–3066, 2000. View at Publisher · View at Google Scholar · View at Scopus
  125. H. Yanagisawa, M. Takamura, E. Yamada et al., “Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship,” Bioorganic & Medicinal Chemistry Letters, vol. 10, no. 4, pp. 373–375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  126. G. R. Madhavan, R. Chakrabarti, R. K. Vikramadithyan et al., “Synthesis and biological activity of novel pyrimidinone containing thiazolidinedione derivatives,” Bioorganic and Medicinal Chemistry, vol. 10, no. 8, pp. 2671–2680, 2002. View at Publisher · View at Google Scholar · View at Scopus
  127. B. B. Lohray, V. Bhushan, B. P. Rao et al., “Novel euglycemic and hypolipidemic agents,” Journal of Medicinal Chemistry, vol. 41, no. 10, pp. 1619–1630, 1998. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. Momose, T. Maekawa, T. Yamano et al., “Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities,” Journal of Medicinal Chemistry, vol. 45, no. 7, pp. 1518–1534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. R. C. Desai, W. Han, E. J. Metzger et al., “5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents,” Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 16, pp. 2795–2798, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. B. Y. Kim, J. B. Ahn, H. W. Lee et al., “Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives,” Chemical and Pharmaceutical Bulletin, vol. 51, no. 3, pp. 276–285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. H. W. Lee, Y. K. Bok, B. A. Joong et al., “Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione,” European Journal of Medicinal Chemistry, vol. 40, no. 9, pp. 862–874, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. K. Liu, L. Xu, J. P. Berger et al., “Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia,” Journal of Medicinal Chemistry, vol. 48, no. 7, pp. 2262–2265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Pinelli, C. Godio, A. Laghezza et al., “Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARα and PPARγ agonist activity,” Journal of Medicinal Chemistry, vol. 48, no. 17, pp. 5509–5519, 2005. View at Publisher · View at Google Scholar · View at Scopus
  134. N. J. Kim, K. O. Lee, B. W. Koo et al., “Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 13, pp. 3595–3598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. K. G. Liu, M. H. Lambert, A. H. Ayscue et al., “Synthesis and biological activity of L-tyrosine-based PPARγ agonists with reduced molecular weight,” Bioorganic & Medicinal Chemistry Letters, vol. 11, no. 24, pp. 3111–3113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  136. B. R. Henke, S. G. Blanchard, M. F. Brackeen et al., “N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents,” Journal of Medicinal Chemistry, vol. 41, no. 25, pp. 5020–5036, 1998. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Takamura, M. Sakurai, E. Yamada et al., “Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents,” Bioorganic and Medicinal Chemistry, vol. 12, no. 9, pp. 2419–2439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  138. Y. Itoh, Y. Kawamata, M. Harada et al., “Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40,” Nature, vol. 422, pp. 173–176, 2003. View at Publisher · View at Google Scholar
  139. E. Christiansen, C. Urban, N. Merten et al., “Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA1/GPR40), a potential target for the treatment of type II diabetes,” Journal of Medicinal Chemistry, vol. 51, pp. 7061–7064, 2008. View at Publisher · View at Google Scholar
  140. E. Christiansen, M. E. Due-Hansen, and T. Ulven, “A rapid and efficient Sonogashira protocol and improved synthesis of free fatty acid 1 (FFA1) receptor agonists,” Journal of Organic Chemistry, vol. 75, no. 4, pp. 1301–1304, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. S. B. Bharate, K. V. Nemmani, and R. A. Vishwakarma, “Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes,” Expert Opinion on Therapeutic Patents, vol. 19, pp. 237–264, 2009. View at Publisher · View at Google Scholar
  142. S. Y. Lu, Y. J. Jiang, J. Lv, T. X. Wu, Q. S. Yu, and W. L. Zhu J, “Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions,” Journal of Molecular Graphics and Modelling, vol. 28, no. 8, pp. 766–774, 2010. View at Publisher · View at Google Scholar
  143. H. Koyama, D. J. Miller, J. K. Boueres et al., “(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents,” Journal of Medicinal Chemistry, vol. 47, no. 12, pp. 3255–3263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. C. Parmenon, J. Guillard, D. H. Caignard et al., “4,4-dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part. II: synthesis and pharmacological evaluation of oxime and acidic head group structural variations,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 10, pp. 2683–2687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. C. Parmenon, J. Guillard, D. H. Caignard et al., “4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: synthesis and pharmacological evaluation,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 5, pp. 1617–1622, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Ohashi, I. Nakagome, J.-i. Kasuga et al., “Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry—activity relationship,” Bioorganic & Medicinal Chemistry, vol. 20, no. 21, pp. 6375–6383, 2012. View at Publisher · View at Google Scholar
  147. I. M. Kapetanovic, “Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach,” Chemico-Biological Interactions, vol. 171, no. 2, pp. 165–176, 2008. View at Publisher · View at Google Scholar
  148. C. Hansch, D. Hoekman, A. Leo, D. Weininger, and C. D. Selassie, “Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology,” Chemical Reviews, vol. 102, no. 3, pp. 783–812, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. C. Hansch, D. Hoekman, and H. Gao, “Comparative QSAR: toward a deeper understanding of chemicobiological interactions,” Chemical Reviews, vol. 96, no. 3, pp. 1045–1075, 1996. View at Publisher · View at Google Scholar · View at Scopus
  150. S. P. Gupta, “QSAR studies on enzyme inhibitors,” Chemical Reviews, vol. 87, no. 5, pp. 1183–1253, 1987. View at Publisher · View at Google Scholar · View at Scopus
  151. B. D. Silverman and D. E. Platt, “Comparative molecular moment analysis (coMMA): 3D-QSAR without molecular superposition,” Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 2129–2140, 1996. View at Publisher · View at Google Scholar · View at Scopus
  152. R. D. Cramer, D. E. Patterson, and J. D. Bunce, “Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins,” Journal of the American Chemical Society, vol. 110, no. 18, pp. 5959–5967, 1988. View at Publisher · View at Google Scholar · View at Scopus
  153. G. Klebe, U. Abraham, and T. Mietzner, “Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity,” Journal of Medicinal Chemistry, vol. 37, no. 24, pp. 4130–4146, 1994. View at Publisher · View at Google Scholar · View at Scopus
  154. H. Gohlke and G. Klebe, “Drugscore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein,” Journal of Medicinal Chemistry, vol. 45, no. 19, pp. 4153–4170, 2002. View at Publisher · View at Google Scholar · View at Scopus
  155. V. Lather, V. Kairys, and M. X. Fernandes, “Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives,” Chemical Biology and Drug Design, vol. 73, no. 4, pp. 428–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  156. L. Rathi, S. K. Kashaw, A. Dixit, G. Pandey, and A. K. Saxena, “Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPARγ agonists,” Bioorganic and Medicinal Chemistry, vol. 12, no. 1, pp. 63–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  157. P. J. Brown, T. A. Smith-Oliver, P. S. Charifson et al., “Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library,” Chemistry and Biology, vol. 4, no. 12, pp. 909–918, 1997. View at Publisher · View at Google Scholar · View at Scopus
  158. M. Scarsi, M. Podvinec, A. Roth et al., “Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor γ activity: a combined virtual screening and biological assay approach,” Molecular Pharmacology, vol. 71, no. 2, pp. 398–406, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. P. Markt, D. Schuster, J. Kirchmair, C. Laggner, and T. Langer, “Pharmacophore modeling and parallel screening for PPAR ligands,” Journal of Computer-Aided Molecular Design, vol. 21, no. 10-11, pp. 575–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. C. Giaginis, S. Theocharis, and A. Tsantili-Kakoulidou, “A consideration of PPAR-γ ligands with respect to lipophilicity: current trends and perspectives,” Expert Opinion on Investigational Drugs, vol. 16, no. 4, pp. 413–417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. N. K. Salam, T. H. Huang, B. P. Kota, M. S. Kim, Y. Li, and D. E. Hibbs, “Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study,” Chemical Biology & Drug Design, vol. 71, no. 1, pp. 57–70, 2008. View at Publisher · View at Google Scholar
  162. Y. Tanrikulu, O. Rau, O. Schwarz et al., “Structure-based pharmacophore screening for natural-product-derived PPARγ agonists,” ChemBioChem, vol. 10, no. 1, pp. 75–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. Y. Tanrikulu, M. Nietert, U. Scheffer et al., “Scaffold hopping by "fuzzy" pharmacophores and its application to RNA targets,” ChemBioChem, vol. 8, no. 16, pp. 1932–1936, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. B. O. Al-Najjar, H. A. Wahab, T. S. Tengku, A. C. Shu-Chien, N. A. Ahmad, and M. O. Taha, “Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling,” European Journal of Medicinal Chemistry, vol. 46, no. 6, pp. 2513–2529, 2011. View at Publisher · View at Google Scholar
  165. D. Barnum, J. Greene, A. Smellie, and P. Sprague, “Identification of common functional configurations among molecules,” Journal of Chemical Information and Computer Sciences, vol. 36, no. 3, pp. 563–571, 1996. View at Google Scholar · View at Scopus
  166. S. Sundriyal, B. Viswanad, P. Ramarao, A. K. Chakraborti, and P. V. Bharatam, “New PPARγ ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 18, pp. 4959–4962, 2008. View at Publisher · View at Google Scholar
  167. H. Zheng, S. Li, L. Ma et al., “A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance,” European Journal of Pharmacology, vol. 659, no. 2-3, pp. 244–251, 2011. View at Publisher · View at Google Scholar
  168. S. Sundriyal, B. Viswanad, E. Bharathy, P. Ramarao, A. K. Chakraborti, and P. V. Bharatam, “New PPARγ ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies,” Bioorganic & Medicinal Chemistry Letters, vol. 18, pp. 3192–3195, 2008. View at Publisher · View at Google Scholar
  169. S. Sundriyal and P. V. Bharatam, “Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening,” European Journal of Medicinal Chemistry, vol. 44, no. 9, pp. 3488–3495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Sundriyal and P. V. Bharatam, “‘Sum of activities’ as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists,” European Journal of Medicinal Chemistry, vol. 44, no. 1, pp. 42–53, 2009. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Choi, Y. Park, H. S. Lee, Y. Yang, and S. Yoon, “1,3-diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists,” Bioorganic and Medicinal Chemistry, vol. 18, no. 23, pp. 8315–8323, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. Z. L. Wei, P. A. Petukhov, F. Bizik et al., “Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation,” Journal of the American Chemical Society, vol. 126, no. 51, pp. 16714–16715, 2004. View at Publisher · View at Google Scholar · View at Scopus
  173. T. Kaya, S. C. Mohr, D. J. Waxman, and S. Vajda, “Computational screening of phthalate monoesters for binding to PPARγ,” Chemical Research in Toxicology, vol. 19, no. 8, pp. 999–1009, 2006. View at Publisher · View at Google Scholar · View at Scopus
  174. V. G. Maltarollo and K. M. Honorio, “Molecular properties of fatty acids related to PPAR binding and metabolic diseases,” Medicinal Chemistry Research, pp. 1–8, 2012. View at Publisher · View at Google Scholar
  175. Y. Ma, S.-Q. Wang, W.-R. Xu, R.-L. Wang, and K.-C. Chou, “Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach,” PloS ONE, vol. 7, no. 6, Article ID e38546, 2012. View at Publisher · View at Google Scholar
  176. L. Michalik, V. Zoete, G. Krey et al., “Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor α helix 12 dynamic behavior,” Journal of Biological Chemistry, vol. 282, no. 13, pp. 9666–9677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  177. J. H. Choi, A. S. Banks, J. L. Estall et al., “Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ 3 by Cdk5,” Nature, vol. 466, no. 7305, pp. 451–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. J. H. Choi, A. S. Banks, T. M. Kamenecka et al., “Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation,” Nature, vol. 477, pp. 477–481, 2011. View at Publisher · View at Google Scholar
  179. J. Jyrkkarinne, J. Kablbeck, J. Pulkkinen et al., “Molecular dynamics simulations for human CAR inverse agonists,” Journal of Chemical Information and Modeling, vol. 52, pp. 457–464, 2012. View at Publisher · View at Google Scholar
  180. D. Genest, N. Garnier, A. Arrault, C. Marot, L. Morin-Allory, and M. Genest, “Ligand-escape pathways from the ligand-binding domain of PPARγ receptor as probed by molecular dynamics simulations,” European Biophysics Journal, vol. 37, no. 4, pp. 369–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  181. V. Zoete, A. Grosdidier, and O. Michielin, “Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 915–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  182. G. Pochetti, N. Mitro, A. Lavecchia et al., “Structural insight into peroxisome proliferator-activated receptor γ binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis,” Journal of Medicinal Chemistry, vol. 53, no. 11, pp. 4354–4366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  183. A. Rogue, C. Spire, M. Brun, N. Claude, and A. Guillouzo, “Gene expression changes induced by PPAR gamma agonists in animal and human liver,” PPAR Research, vol. 2010, Article ID 325183, 16 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  184. A. Rogue, M. P. Renaud, N. Claude, A. Guillouzo, and C. Spire, “Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes,” Toxicology and Applied Pharmacology, vol. 254, no. 1, pp. 18–31, 2011. View at Publisher · View at Google Scholar · View at Scopus